These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36871011)

  • 1. CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting.
    Huang Q; Zhang XH; Liu D
    J Hematol Oncol; 2023 Mar; 16(1):18. PubMed ID: 36871011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.
    Liu J; Zhang Y; Guo R; Zhao Y; Sun R; Guo S; Lu W; Zhao M
    Front Immunol; 2023; 14():1170968. PubMed ID: 37215124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
    Watanabe N; Mo F; Zheng R; Ma R; Bray VC; van Leeuwen DG; Sritabal-Ramirez J; Hu H; Wang S; Mehta B; Srinivasan M; Scherer LD; Zhang H; Thakkar SG; Hill LC; Heslop HE; Cheng C; Brenner MK; Mamonkin M
    Mol Ther; 2023 Jan; 31(1):24-34. PubMed ID: 36086817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Base-edited CAR T cells for combinational therapy against T cell malignancies.
    Georgiadis C; Rasaiyaah J; Gkazi SA; Preece R; Etuk A; Christi A; Qasim W
    Leukemia; 2021 Dec; 35(12):3466-3481. PubMed ID: 34035409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
    Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L
    Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
    Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
    Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
    Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
    Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
    Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting.
    Zhang W; Li S; Long J; Xie S; Wang M; Liu H; Xu Z
    Exp Hematol Oncol; 2024 Apr; 13(1):43. PubMed ID: 38637863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies.
    Wei W; Ma H; Yang D; Sun B; Tang J; Zhu Y; Chen X; Huang X; Liu J; Hu Z; Liu T; Zou L; Zhao X
    Blood Adv; 2023 Jul; 7(13):2941-2951. PubMed ID: 36848638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
    Xie L; Ma L; Liu S; Chang L; Wen F
    Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting.
    Wang JN; Gu T; Hu Y; Huang H
    Exp Hematol Oncol; 2022 Sep; 11(1):61. PubMed ID: 36153595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
    Chen D; You F; Xiang S; Wang Y; Li Y; Meng H; An G; Zhang T; Li Z; Jiang L; Wu H; Sheng B; Zhang B; Yang L
    Am J Cancer Res; 2021; 11(11):5263-5281. PubMed ID: 34873460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
    Cooper ML; DiPersio JF
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
    Lu P; Liu Y; Yang J; Zhang X; Yang X; Wang H; Wang L; Wang Q; Jin D; Li J; Huang X
    Blood; 2022 Jul; 140(4):321-334. PubMed ID: 35500125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019.
    Bukhari A; Siglin J; Lutfi F; Kansagra AJ; Yared J; Rapoport AP; Dahiya S
    Crit Rev Oncol Hematol; 2020 Aug; 152():103007. PubMed ID: 32505824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
    Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
    Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia.
    Zhao J; Song Y; Liu D
    J Hematol Oncol; 2019 Feb; 12(1):17. PubMed ID: 30764841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.
    You F; Wang Y; Jiang L; Zhu X; Chen D; Yuan L; An G; Meng H; Yang L
    Am J Cancer Res; 2019; 9(1):64-78. PubMed ID: 30755812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells.
    Feng J; Xu H; Cinquina A; Wu Z; Zhang W; Sun L; Chen Q; Tian L; Song L; Pinz KG; Wada M; Jiang X; Hanes WM; Ma Y; Zhang H
    Front Immunol; 2022; 13():997482. PubMed ID: 36172388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.